FDA inspection report slams Emergent for quality and cleanliness breaches at Bayview facility
Company failed to investigate vaccine drug substance discrepancies thoroughly, says US regulator
A US Food and Drug Administration inspection of Emergent BioSolutions’ Bayview facility where Johnson & Johnson’s COVID-19 shot is manufactured found that the pharma contractor failed to investigate vaccine drug substance ingredient discrepancies thoroughly amid several cleanliness and quality control breaches.
Earlier this month, a batch of a key ingredient for the J&J single-shot vaccine at the Baltimore facility failed to meet quality control standards and up to 15 million doses were lost.
As a result, the US government asked J&J to take charge of production at Bayview, although manufacturing at the facility was halted earlier this week pending the results of the FDA inspection.
Published on Wednesday, the so-called ‘FDA Form 483’ report said Emergent failed to properly review personnel movements in and around the facility as a potential source of contamination, and did not consider that its raw material storage could be prone to contamination.
Once the ingredient mix-up was identified, no extra cleaning was performed beyond standard practices and the FDA came away with the verdict that “there is no assurance that other batches have not been subject to cross-contamination.”
“During an inspection of Emergent BioSolutions that ended Tuesday, the FDA cited a number of observations concerning whether the facility’s processes met our requirements and standards,” the FDA said.
Among the FDA’s other observations were concerns about unsanitary conditions at the facility, such as waste not being correctly decontaminated and being transported through the warehouse before disposal.
Peeling paint on walls and wall damage at the factory were deemed to impact Emergent’s “ability to adequately clean and disinfect the area,” the FDA report said.
The FDA also said the size and design of the facility in relation to the volume of production it was undertaking was not suitable “to facilitate cleaning, maintenance, and proper operations.”
“We deeply value the relationship we have with our manufacturing partners and with the FDA,” Emergent said in a statement. “The FDA’s feedback will help us continue to improve and strengthen the supply chain for Johnson & Johnson’s COVID-19 vaccine. While we are never satisfied to see shortcomings in our manufacturing facilities or process, they are correctable and we will take swift action to remedy them.”
The FDA said that at the agency’s request, Emergent BioSolutions has agreed to pause new production while it works to resolve the potential quality issues.
“For the vaccines already manufactured, the products will undergo additional testing and will be thoroughly evaluated to ensure their quality before any potential distribution. We will not allow the release of any product until we feel confident that it meets our expectations for quality,” the FDA said.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance